These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28248984)

  • 21. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
    PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.
    Aboutorabi A; Hadian M; Ghaderi H; Salehi M; Ghiasipour M
    Glob J Health Sci; 2014 Aug; 7(1):98-106. PubMed ID: 25560346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
    Hajjar A; Ergun MA; Alagoz O; Rampurwala M
    PLoS One; 2019; 14(6):e0217778. PubMed ID: 31166995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
    Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
    Niraula S; Gyawali B
    Breast Cancer Res Treat; 2019 Jan; 173(1):103-109. PubMed ID: 30238273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
    Diaby V; Ali AA; Williams KJ; Ezendu K; Soto-Perez-de-Celis E; Chavarri-Guerra Y; de Lima Lopes G
    Breast Cancer Res Treat; 2017 Dec; 166(3):951-963. PubMed ID: 28840424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
    Dedes KJ; Szucs TD; Imesch P; Fedier A; Fehr MK; Fink D
    Ann Oncol; 2007 Sep; 18(9):1493-9. PubMed ID: 17761705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
    Gyawali B; Niraula S
    Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis.
    Doan TN; Barendregt J
    Swiss Med Wkly; 2019 May; 149():w20082. PubMed ID: 31104310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.